Autopsy report · NCT03791060
Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Cause of deathStaffing, sites or logistics
“Study halted prematurely due COVID-19 pandemic and did not resume; participants are no longer being examined or receiving intervention.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years before it stopped.
- 4 participants enrolled.
- Results were posted on the registry 3 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Beth Israel Deaconess Medical Center
- Sponsor type
- University, hospital or other
- Conditions
- Necrobiosis Lipoidica Diabeticorum
- Interventions
- Secukinumab
- Participants
- 4
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Comparison of Efficacy of Behavioral Approaches for Treatment of Insomnia
“Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. COVID Complications.” - FMT for MDRO Colonization After Infection in Renal Transplant Recipients
“This study was paused and was not resumed due to the COVID-19 pandemic.” - Perception-Action Approach vs. Passive Stretching for Infants With Congenital Muscular Torticollis
“Study stopped due to COVID-19 pandemic and will not resume.” - Zambia Common Elements Treatment Approach Pilot Study
“COVID-19 precluded the study team from being able to complete all follow-up assessments.The study was halted on March 17, 2020 and did not resume.” - PALS for Nutrition Education
“COVID-19 paused study temporarily due to no clinical encounters”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.